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Supplementary methods 
Search strategies 
The following terms were used in each database, for the time periods described.  
Database: Ovid MEDLINE(R) 1946 to April Week 1 2015 
Search Strategy: 
1     alpha 1-Antitrypsin/  
2     alpha-1 antitrypsin.ti,ab.  
3     alpha 1 antitrypsin.ti,ab.  
4     alpha1 antitrypsin.ti,ab.  
5     alpha-1-at.ti,ab.  
6     alpha-1-antitrypsin.ti,ab.  
7     alpha one antitrypsin.ti,ab.  
8     alpha one antitrypsin.ti,ab.  
9     AAT.ti,ab.  
10     A1AT.ti,ab.  
11     AATD.ti,ab.  
12     deficien$ or lack$.ti,ab.  
13     alpha 1-Antitrypsin Deficiency/  
14     or/1-10  
15     12 and 14  
16     11 or 13 or 15  
17     limit 16 to humans  
 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations April 09, 2015 
Search Strategy: 
1     alpha-1 antitrypsin.ti,ab.  
2     alpha 1 antitrypsin.ti,ab.  
3     alpha1 antitrypsin.ti,ab.  
4     alpha-1-at.ti,ab.  
5     alpha-1-antitrypsin.ti,ab.  
6     alpha one antitrypsin.ti,ab.  
7     alpha one-antitrypsin.ti,ab. 
8     alfa 1 antitrypsin.ti,ab.  
9     AAT.ti,ab.  
10     A1AT.ti,ab.  
11     AATD.ti,ab.  
12     deficien$ or lack$.ti,ab.  
13     or/1-10  
14     12 and 13  
15     11 or 14  
 
Database: Embase (Ovid) 1974 to 2015 April 09 
Search Strategy: 
1     alpha-1 antitrypsin.ti,ab.  
2     alpha 1 antitrypsin.ti,ab.  
3     alpha1 antitrypsin.ti,ab.  
4     alpha-1-at.ti,ab.  
5     alpha-1-antitrypsin.ti,ab.  
6     alpha one antitrypsin.ti,ab.  
7     alpha one-antitrypsin.ti,ab.  
8     alfa 1 antitrypsin.ti,ab.  
9     AAT.ti,ab.  
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10     A1AT.ti,ab.  
11     or/1-10  
12     deficien$. or lack$.ti,ab.  
13     11 and 12  
14     AATD.ti,ab.  
15     exp alpha 1 antitrypsin deficiency/  
16     13 or 14 or 15  
 
Databases : Cochrane Library (Wiley) CENTRAL issue 3 of 12 2015, CDSR Issue 4 of 12 2015, HTA, 
EED and DARE Issue 1 of 4 
Search date: 10/04/2015 
Search strategy:  
#1 "alpha-1 antitrypsin"  
#2 "alpha 1 antitrypsin"  
#3 "alpha1 antitrypsin"  
#4 "alpha-1-at"  
#5 "alpha-1-antitrypsin"  
#6 "alpha one antitrypsin"  
#7 "alpha one-antitrypsin"  
#8 "alfa 1 antitrypsin"  
#9 deficien* or lack*  
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8  
#11 #9 and #10  
#12 AATD  
#13 MeSH descriptor: [alpha 1-Antitrypsin Deficiency] explode all trees 
#14 #11 or #12 or #13 
 
Correspondence and clarification 
E-mail correspondence with Professor A Dirksen (26/02/2016) in regards to:
1
 
 Clarification for the method used for the physiological adjustment for CT lung density was confirmed 
to be the same as previous published work.
2
 
E-mail correspondence with Professor A Dirksen (26/02/2016) in regards to:
2
 
 Request for unpublished SGRQ raw summary data to enable meta-analysis. Data kindly supplied by 
Grifols. 
E-mail contact with Professor K Chapman (24/02/2016) in regards to
3
 including response from CSL Behring: 
 Clarification of typographical error in Table 2 of published manuscript3 for units of DLCO values 
should be mL/mmHG/min. 
 Clarification of differences in data between ClinicalTrials.Gov and published manuscript for change in 
DLCO. Published manuscript included correct descriptive results and ClinicalTrials.Gov also includes 
ANCOVA analysis. 
 Clarification for the method used for the physiological adjustment for CT lung density was confirmed 
to be the same as previous published work.
2
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Custom bias assessment tool for non-randomised studies. 
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Supplementary results 
Supplementary table 1: Characteristics of included studies 
In the interest of brevity only inclusion criteria has been included in the table. 
Placebo Controlled RCTs of augmentation 
Author 
Year  
Population Inclusion 
Criteria 
Participants Intervention (N) Comparator (N) Outcomes 
Dirksen 
19991 
PiZZ phenotype; moderate to 
severe emphysema; FEV1 
30% - 80% of predicted. 
N= 58 
Recruited from both the Danish and Dutch 
AATD Registries 
Mean FEV1% predicted (SD): 
Int: 50·0 (15·9) 
Cont: 46·2 (11·9) 
AAT Augmentation(n=28 ) 
250mg/kg body weight 
intravenously infused every 4 
weeks. 
Minimum treatment duration of 
3 years. 
Placebo (n=28 ) 
Human albumin in an isotonic 
solution 625mg/kg body weight 
infused every 4 weeks.  
Minimum treatment duration of 
3 years. 
Lung Function - FEV1, SVC, KCO, DLCO 
and patient-administered serial spirometry - 
no differences between treatment groups  
Lung density - Annual rate of decrease in 
lung density measured by CT scan. 
Treatment significantly slowed lung density 
decline. Study underpowered for this 
outcome. 
Dirksen 
20092 
AAT -serum concentrations 
<11μM; ≥18yrs; ≥1 
exacerbation in past 2 years; 
post bronchodilator FEV1% 
≥25% and ≤80% with 
FEV1/FVC ratio ≤0·70; 
Normal Spirometry could be 
included if KCO was ≤80%; 
Weight 42kg-92kg; 
N=82 
77 randomised across 3 sites in Denmark, 
Sweden and the UK. 
Mean Age (yrs.) (SD): 
Int: 54·7 (8·4) 
Cont: 55·3 (9·8) 
Sex (male) n (%): 
Int: 25 (65·8) 
Cont: 16 (41·0) 
Mean FEV1% predicted (SD): 
Int: 46·3 (19·6) 
Cont: 46·6 (21·0) 
AAT Augmentation (n= 35) 
Prolastin: 60mg/kg body weight 
intravenously infused weekly. 
2 year treatment.  
Additional optional 6 month 
open label extension study. 
Placebo (n= 32) 
2% human albumin infused 
weekly. 
2 year treatment.  
Additional optional 6 month 
open label extension study. 
Lung Density – Trend for rate of lung density 
slower in treatment not significant. 
Pulmonary Exacerbations – No difference in 
patient reported exacerbation frequency. Post 
hoc analysis showed proportionally fewer 
‘severe’ exacerbations in active treatment 
group. 
Lung Function - FEV1, DLCO and KCO all 
demonstrated no significant differences 
between treatment groups. 
Mortality-Nil 
Quality of life – SGRQ no differences in 
groups 
Adverse events – Safe and well tolerated. 
Chapman 
20153 
Aged 18-65years; 
emphysema 2o AATD; 
serum AAT ≤11μM; FEV1 
35-70% predicted.  
N=180 
180 randomised across 28 sites in 13 
countries. 
Mean Age (yrs.) (SD): 
Int: 53·8 (6·9) 
Cont: 52·4 (7·8) 
Sex (male) n (%): 
Int: 48 (51·6) 
Cont: 50 (57·5) 
Mean FEV1% predicted (SD): 
Int: 47·4 (12·1) 
Cont: 47·2 (11·1) 
AAT Augmentation (n=93)  
Zemaira: 60mg/kg/week 
Investigational product: 
AAT60mg/kg body weight 
intravenously infused weekly. 
2 year treatment. Additional 
optional 2 year open label 
extension study in non-US 
countries. 
Placebo (n=87) 
Lyophilized preparation 
60mg/kg body weight 
intravenously infused weekly. 
2 year treatment. Additional 
optional 2 year open label 
extension study in non-US 
countries. 
Adverse events – Safe and well tolerated. 
Lung density - Annual rate of decrease in 
lung density measured by CT scan. 
Treatment group significantly slowed lung 
density decline. 
Mortality – 1death in treatment group, 3 
deaths in control group. 
Pulmonary exacerbations - time to first 
exacerbation,  
rate, duration and severity of exacerbations. 
No differences 
Lung Function - FEV1, FEV1/FVC, FVC, 
DLCO no significant or clinical differences. 
Quality of Life – SGRQ showed no 
significant or clinical differences. 
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Other AAT augmentation studies 
Author year  
Study design  
Population Inclusion 
Criteria 
Participants Intervention (N) Comparator (N) Outcomes 
Weber 19874 
 
Uncontrolled 
Observational 
PiZZ AATD, clinical 
evidence of progressive 
emphysema, non-smoking. 
N= 10 
Three centre study in Germany with average 
pre inclusion follow up of 2·5 years. 
Of the completers: 
Mean Age (yrs.) (SD): 
Int: 48 (5) 
Sex (male) n (%): 
Int: 7 (70) 
AAT Augmentation (n=10) 
AAT Augmentation: AAT 
60mg/kg body weight 
intravenously infused weekly. 
Up to 18 months treatment. 
 Biochemical – achieved a-priori serum AAT 
trough levels.  
Adverse Events – Safe and well tolerated 
Lung Function – No Change in lung function 
Wewers 19875 
 
Controlled 
Observational 
PiZZ AATD, Clinical 
evidence of destructive lung 
disease. 
N=30 
Single centre recruitment from National Heart, 
Lung and Blood Institute (NHLBI), USA. 
Mean Age (yrs.) (SEM): 
Int: 46 (2) 
Cont: 28 (3) 
Sex (male) n (%): 
Int: 18 (85·7) 
Cont: 6 (66·7) 
Mean FEV1% predicted (SEM): 
Int: 37 (3) 
Cont: n/a 
AAT Augmentation (n= 21) 
AAT Augmentation: AAT 
60mg/kg body weight 
intravenously infused weekly. 
Up to 6 months treatment.  
Control = 9 
No intervention participants 
with PiMM phenotype, normal 
levels of AAT 
Lung Function – No changes in lung function 
observed over the 6 months.  
Adverse Events – No severe adverse 
reactions observed. Only 4 “important” 
adverse events  
Biochemical – Biochemical efficacy in 
raising Serum and fluid in the epithelial 
lining of the lungs AAT trough 
levels(p<0·0001), Serum and fluid in the 
epithelial lining of the lungs anti-neutrophil 
elastase(p<0·0001). 
Schmidt 19886 
 
Uncontrolled 
Observational 
AATD PiZZ phenotype with 
COPD 
N= 20 
Recruited from 3 sites in Germany. 
Mean Age (yrs.) (SD): 
46·6 (7·6) 
Sex (male) n (%): 
15 (75) 
Mean FEV1 L(SD) n=17: 
1·1(0·32) 
AAT Augmentation (n= 20 ) 
AAT (Cutter Biological 
of Miles Inc., Berkeley, 
California) 60mg/kg body 
weight intravenously infused 
weekly. 
Up to 6 months treatment.  
 Adverse Events – Well tolerated and safe. 
Biochemical – Effective at augmenting 
circulating serum AAT. 
Barker 19947 
 
Uncontrolled 
Observational/ 
Retrospective 
chart review. 
AATD PiZZ phenotype. N= 14 
Recruited from NHLBI National AAT Registry 
USA.  
Mean Age (yrs.) (SD): 
50 (6·16) 
Sex (male) n (%): 
10 (71·4) 
Mean FEV1 L (SD): 
1·11 (n/a) 
AAT Augmentation (n=14) 
Prolastin 60mg/kg body weight 
intravenously infused every 4 
weeks. 
48 months  
 Adverse Events – Similar safety profile to 
previously reported data. 
Lung Function –No statistical differences 
before and after treatment 
Miravitlles 
19948 
 
Uncontrolled 
Observational 
Plasma AATD <35% of 
normal, PiZZ PiNullNull or 
PiZNull, non smoker, aged 
18-75, clinical/radiological 
evidence of Emphysema and 
compatible 
PFT’s(FEV1<80% and/or 
RV>140% of predicted). 
N= 13 
Recruited from single centre in Italy . 
Of the completers: 
Mean Age (yrs.) (SD): 
46·6 (9·4) 
Sex (male) n (%): 
6 (46·1) 
Mean FEV1% predicted (SD): 
AAT Augmentation (n= 13) 
Prolastin 60mg/kg body weight 
intravenously infused every 
week for four weeks then 
240mg/kg body weight 
intravenously infused every 
four weeks. 
Minimum treatment duration of 
 Adverse Events – Safe and well tolerated. 
Biochemical – 3 of 16 participants did not 
achieve a ‘protective’ level of AAT. 
Lung Function – Insufficient data for 
statistical analysis. 
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26 (9·3) 3 years. 
Barker 19979 
 
Uncontrolled 
Observational 
AATD serum AAT levels of 
<50 mg/dL and PIZ 
genotype; airflow 
obstruction with an 
FEV1<75% of predicted; 
non/ex-smoker >1year; 
AAT augmentation therapy 
> 6 months prior to study 
entry. 
N= 23 
Patients referred from 4 states across the USA. 
Mean Age (yrs.) (SD): 
51·1 (7·2) 
Sex (male) n (%): 
18 (65·2) 
Mean FEV1 1 L(SD): 
1·22 (0·56) 
AAT Augmentation (n=23 ) 
Prolastin-C 120 mg/kg body 
weight every 2 weeks for a total 
of 9 infusions over a period of 
16 weeks. A 10th infusion was 
administered at week 20, 4 
weeks later. 
20 month study duration. 
 
 
Adverse Events - No patient required 
interruption or discontinuation of infusion. 
There were no other deaths or serious 
adverse events.  
Biochemical – No participants maintained 
AAT levels >80mg/dl >7 days. 
Lung Function - FEV1, FVC. No clinically 
or significant changes 
Schwaiblmair 
199710 
 
Uncontrolled 
Observational. 
AAT PiZZ, PiSZ phenotype; 
clinical evidence of 
destructive lung disease. 
N= 20 
Single centre recruitment in Germany. 
Mean Age (yrs.) (SD): 
48·8 (1·8) 
Sex (male) n (%): 
11 (55) 
Mean FEV1% predicted (SD): 
41·7 (3·1) 
AAT Augmentation (n= 20) 
AAT Augmentation: 60mg/kg 
once a week. 
Minimum treatment duration of 
3 years. 
 Adverse Events – Safe and well tolerated. 
Biochemical – Mean Serum AAT adequately 
augmented. 
Lung Function - FEV1, FVC, TLCO, 
MEF50, RV, TLC at 12, 24 and 36 months. 
No changes  
Seersholm 
199711 
 
Observational 
Controlled 
study. 
PiZZ or AAT serum level 
<12 μmol·L; either FEV1 
<65% predicted or annual 
decline in FEV1 >120mL; 
non/ex-smoking at 
enrolment; recipient of AAT 
augmentation therapy ≥1 
yr.; ≥2 spirometries ≥1yr 
apart. 
 performed during the 
treatment period; index 
cases; >25 yrs. of age at 
entry. 
N= 295 
Recruited from 25 centres across Germany and 
from the Danish AATD Registry 
Mean Age (yrs.) (SD): 
Int: 46 (8) 
Cont: 45 (10) 
Sex (male) n (%): 
Int: 142 (71·7) 
Cont: 55 (56·7)  
Mean FEV1% predicted (SD): 
Int: 37 (14) 
Cont: 42 (10) 
AAT Augmentation (n= 198) 
Prolastin: infused weekly at 60 
mg/kg body weight  
Mean follow up duration 
3·2±1·6 years. 
Control (n= 97) 
Normal clinical treatment with 
no AAT augmentation therapy 
Mean follow up duration 
5·8±3·4 years. 
Lung Function – 22ml/yr. Slower decline in 
FEV1in treatment group across all 
patients(p=0·02). 
No significant difference in change in FEV1 
between the treated group and the untreated 
group among the patients with the lowest and 
the highest FEV1% pred.  
In patients with initial FEV1 of 31–65% 
predicted, significantly lower rate of decline 
in FEV1 among the treated patients (p= 
0·04). 
The Alpha-1-
Antitrypsin 
Deficiency 
Registry 
Study Group 
199812 
 
Observational 
Controlled 
study 
>18 yr. of age; either AAT 
serum <11mMol or PiZZ 
genotype. 
N= 1129 
Patients from NHLBI AATD Registry USA. 
1048 patients used in Survival analysis (no 
demographics) & 927 used for FEV1 slope 
analysis. 
Of the 927: 
Mean Age (yrs.) (SD): 
Int Grp 1: 46 (11) 
Int Grp 2: 47 (10) 
Cont: 43 (12) 
Sex (male) n (%): 
Int Grp 1: 227 (58·1) 
Int Grp 2: 206 (57·9) 
Cont: 187 (49·1) 
Mean FEV1% predicted (SD): 
Int Grp 1: 37 (18) 
Int Grp 2: 41 (21) 
AAT Augmentation (n= 747 in 
two groups: 
1)390 always received therapy, 
and  
2)357 partly receiving therapy 
while in the Registry) 
Prolastin 60mg/kg body weight 
intravenously infused weekly. 
Up to 7 years follow up. 
Control (n= 382) 
Normal care naive to AAT 
augmentation 
Lung Function – Overall change in FEV1 
was not significantly different between 
groups.  
Subgroup into GOLD disease severity by 
FEV1 decline is slowest in those receiving 
augmentation p=0·03. 
Survival – Across all patients no changes. 
Those with FEV1<50% saw significantly 
higher (p < 0·001) mortality in subjects who 
never as opposed to sometimes or always 
received augmentation therapy. 
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Cont: 74 (35) 
Wencker 
199813 
 
Uncontrolled 
Observational 
>18 yrs.; AATD; 
FEV1<65% predicted, or 
annual decline of 
FEV1>120 mL; non/ex-
smoker >3 months prior to 
the first infusion. 
N= 443 
Patients from 25 centres throughout Germany. 
Mean Age (yrs.) (SD): 
47 (9) 
Sex (male) n (%): 
292 (65·9) 
Mean FEV1% predicted (SD): 
Exsmokers:35·5 (14·8) 
Non-Smokers: 42·2 (18·2) 
Of 287 patients included in FEV1 Longitudinal 
follow up: 
Mean Age (yrs.) (SD): 
46 (9) 
Sex (male) n (%): 
187 () 
Mean FEV1% predicted (SD): 
36·3 (15·2) 
AAT Augmentation (n= 443) 
Prolastin 60mg/kg body weight 
intravenously infused weekly. 
Registry study and treatment 
duration varied. 
 Lung Function - FEV1 decline showed no 
differences.  
Subgroup analysis observed those with 
FEV1<30% predicted had a significantly 
slower rate of decline of FEV1 than those 
with FEV1>30% . 
Adverse Events – Safe and well tolerated. 
Wencker 
200114 
 
Observational 
Controlled 
study 
AATD serum levels , 35% 
of normal regardless of 
phenotype; FEV1≤65% 
predicted or decline in 
FEV1 of . 120 mL/yr.; non-
smokers or ex-smokers >3 
months. 
N= 96 
Data taken from the Wissenschaftliche 
Arbeitsgemeinschaft zur Therapie von 
Lungenkrankungen (WATL) Germany. 
Baseline demographics: 
Mean Age (yrs.) (SD): 
Int: 44·3 (8·6) 
Sex (male) n (%): 
Int: 62 (64·6) 
Mean FEV1% predicted (SD): 
Int: 41·0 (17·3) 
AAT Augmentation (n= 96) 
Prolastin: 60mg/kg body weight 
intravenously infused weekly. 
Mean follow-up after start of 
augmentation was 50·2 (30·2) 
months. 
Control (n=96) 
Control group was the same 
cohort with data taken from at 
least the year prior to 
commencement of treatment. 
Mean follow-up before 
augmentation was 47·5 (28·1) 
months.  
Lung Function - FEV1 declined significantly 
slower (p=0·019) after starting therapy -
34·3±29·7(SD)mL/yr. than prior to therapy 
with AAT augmentation -49·2± 60·8 mL/yr. 
Stoller 200215 
 
RCT 
AATD serum levels <11 
mol/L; airflow obstruction, 
post-bronchodilator FEV1 
30-80% of predicted or an 
FEV1/FVC of <0·70, if 
FEV1>80%; DLCO <70%; 
emphysema on CT scan; 
non-smoking ≥6 months; 
>18 years; adequate 
contraception. 
N= 28 
Multi-centre study in USA. 
Mean Age (yrs.) (SD): 
Int: 45 (11) 
Cont: 49 (7) 
Sex (male) n (%): 
Int: 10 (71·4) 
Cont: 11 (78·6)  
Mean FEV1% predicted (SD): 
Int: 48 (18) 
Cont: 46 (15) 
AAT Augmentation (n= 14) 
Respitin: 60mg/kg body weight 
intravenously infused weekly. 
Respitin for 10 weeks, after 
which all subjects received 
Respitin at the same dose for a 
total study duration of up to 2 
years. 
Control (n=14 ) 
Prolastin: 60mg/kg body 
weight intravenously infused 
weekly. 
Prolastin for 10 weeks, after 
which all subjects received 
Respitin at the same dose for a 
total study duration of up to 2 
years. 
Adverse Events – No differences, safe and 
well tolerated. 
Biochemical – Biochemically effective and 
comparable with control. 
Lung Function - FEV1, FVC, DLCO No 
Changes observed. 
Stoller 200316 
 
Observational 
Controlled 
study 
Age >18 years; serum AAT 
level 11 mol/L; or a ZZ or 
Znull phenotype;  
N= 1129 
Patients were from the NHLBI AATD Registry 
USA. 
Mean Age (yrs.) (SD): 
47 (9) 
Sex (male) n (%): 
292 (65·9) 
Subgroups - always (Grp1), partly (Grp2) or 
AAT Augmentation (n= 747 in 
two groups 1) 390 always 
received therapy, and  
2) 357 were partly receiving 
therapy while in the Registry) 
AAT60mg/kg body weight 
intravenously infused weekly. 
Follow up 3·5-7 years. 
Control (n=382) 
Normal care naive to AAT 
augmentation 
Adverse events – Participants receiving 
weekly infusions reported a higher rate and 
severity of AE’s than those treated every 2 to 
3 weeks (p=0·020 and p=0·003) or monthly 
(p=0·001 and p=0·014).  But compared to 
literature safe and well tolerated  
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never (Grp3) receiving AAT therapy: 
Mean Age (yrs.) (SD): 
Grp 1: 48 (9) 
Grp 2: 47 (10) 
Grp 3: 45 (12) 
Sex (male) n (%): 
Grp 1: 226 (58) 
Grp 2: 204 (57) 
Grp 3: 197 (52) 
Mean FEV1% predicted (SD): 
Grp 1: 37 (18) 
Grp 2: 37 (21) 
Grp 3: 65 (37) 
Stocks 200617 
 
RCT 
18-70 years; males & post-
menopausal females or non-
pregnant, non-lactating 
females using reliable 
contraceptive; AATD serum 
AAT <11 µM and 
genotypes: PiZZ, PiZ null, 
or PiNullNull; CT evidence 
of emphysema; plus ≥1 of 
the following: chest X-ray 
evidence of lung 
destruction, FEV1≤80% , 
FEV1 decline of ≥35 
mL/year or FEV1≥18% of 
predicted; no AAT 
augmentation ≥4 weeks 
prior to screening visit. 
N= 44 
Recruited from both the Danish and Dutch 
AATD Registries 
Mean Age (yrs.) (SD): 
Int: 50(7) 
Cont: 56(9) 
Sex (male) n (%): 
Int: 21(70%) 
Cont: 7(50%)  
Mean FEV1% predicted (SD): 
Int: 48·0(22·2) 
Cont: 45·2 (16·7) 
AAT Augmentation (n= 30) 
Zemira: 60mg/kg body weight 
intravenously infused weekly. 
24 weeks treatment 
Control (n= 14) 
Prolastin: 60mg/kg body 
weight intravenously infused 
weekly for 10 weeks. Then 
crossed over to receive Zemira 
for a further 14 weeks 
treatment. 
 
Adverse events – Comparatively safe and 
well tolerated. 1 death in the placebo group.  
Biochemical – Not inferior to control drug. 
Campos 
200918 
 
Uncontrolled 
Observational 
AATD;-members of 
AlphaNet (a not-for-profit 
health management 
company responsible for co-
ordinating services 
for subjects with AATD), 
AAT augmentation 
recipient; presence of 
obstructive lung disease  
N= 1062 
Participants were members of AlphaNet USA. 
Of the 922 eligible: 
Mean Age (yrs.) (SD): 
Int: 54·5(9·6) 
Sex (male) n (%): 
Int: 485(52·6) 
Mean FEV1% predicted (SD): 
Int: 37·5 (19) 
AAT Augmentation (n=922 ) 
Augmentation type and 
duration not available· All had 
been established on treatment 
for 12 months prior to inclusion 
to study. 
 Health Status - No clinically significant 
changes in SGRQ 
Exacerbation Rates – oldest sub group had 
significantly lower exacerbations (p<0·05) 
Health Care Utilisation - No differences pre 
and post treatment 
Campos 
200919 
 
Uncontrolled 
Observational 
AATD;-members of 
AlphaNet, AAT 
augmentation recipient; 
presence of obstructive lung 
disease 
N= 1062 
Members of AlphaNet USA. 
Of the 922 eligible: 
Mean Age (yrs.) (SD): 
Int: 54·5(9·6) 
Sex (male) n (%): 
Int: 485(52·6) 
Mean FEV1% predicted (SD): 
Int: 37·5 (19) 
AAT Augmentation (n= ) 
Prolastin: intravenously infused 
data on dosing and frequency 
was unavailable. 
 Health Status - No clinically significant 
changes in SGRQ  
Exacerbation – No significant differences in 
frequency. 
 
Supplementary material - Edgar RG et al - International Journal of COPD March 2017 
9 
 
Tonelli 200920 
 
Observational 
Controlled 
study 
AATD PIZZ genotype; ≥2 
post bronchodilator FEV1, 
≥6 months apart. 
N=164 
The Alpha-1 Foundation DNA and Tissue 
Bank. Multiple sites across the USA 
Mean Age (yrs.) (SE): 
Int: 61·3(0·7) 
Cont:65·1(1·9) 
Sex (male) n (%): 
Int: 59(47·6) 
Cont: 20(50) 
Mean FEV1% predicted (SE): 
Int: 43(2) 
Cont: 77(5) 
AAT Augmentation (n=124) 
The augmentation therapy used 
was predominantly weekly 
intravenous Prolastin 
60mg/kg/week (88% of 
patients) but also Aralast and 
Zemaira. Insufficient data on 
dosing and frequency. 
Patients were on their own Rx 
and study team had no input.  
Mean follow up of 41·7 
months. 
Control (n=40) 
Usual care no augmentation 
therapy 
Lung Function - statistical difference 
(p=0·05) in FEV1 decline between 2 groups, 
augmented group FEV1=10·61± 21·4 mL/yr. 
non-augmented group FEV1 -36·96 ± 12·1 
mL/yr.  
Survival - No differences were observed in 
the 5-year mortality rate. 
Stocks 201021 
 
RCT 
Double-blind 
crossover 
≥ 18 years; AATD genotype 
PiZZ, PiZ Null, PiNullNull 
and serum levels of < 11 
μM, or other predefined “at-
risk” alleles; recipient of 
augmentation therapy with 
Prolastin for at least 1 
month prior to study start; 
FEV1 20%-80% predicted 
value within the previous 6 
months. 
N= 24 
Multi-centre 16-week crossover study USA. 
Mean Age (yrs.) (SD): 
Int: 57·0(9·33) 
Cont: 58·4(6·86) 
Sex (male) n (%): 
Int: 4(33·3) 
Cont: 6(50·0) 
Mean FEV1% predicted (SD): 
Int: 43·8(13·2) 
Cont: 41·8(13·8) 
AAT Augmentation (n=12) 
Prolastin/Prolastin-C: Weekly 
intravenous infusions of 60 
mg/kg body weight of Prolastin 
for 8 weeks followed by weekly 
intravenous infusions of 60 
mg/kg body weight of 
Prolastin-C for 8 weeks 
followed by an 8 week open 
label study with 60 mg/kg 
Prolastin-C 
Control (n=12) 
ProlastinC/Prolastin: Weekly 
intravenous infusions of 60 
mg/kg body weight of 
Prolastin-C for 8 weeks 
followed by weekly 
intravenous infusions of 60 
mg/kg body weight of Prolastin 
for 8 weeks followed by an 8 
week open label study with 60 
mg/kg Prolastin-C 
Adverse Events - No difference. Safe and 
well tolerated. 
Biochemical – no inferiority in treatment was 
observed. 
Exacerbation Rate – No difference 
Vidal 201022 
 
Uncontrolled 
Observational 
AATD with pulmonary 
emphysema; recipient or 
planned recipient of AAT 
augmentation 
N= 23 
9 Hospital sites across Spain. 
Median Age (yrs.) (IQR): 
Int: 49(43-61) 
Sex (male) n (%): 
Int: 11(47·8) 
Median FEV1% predicted (IQR): 
Int: 46·3(39·0-58·0) 
AAT Augmentation (n=23) 
Trypsone: Infusions of 
60mg/kg  
5 Subjects – 60mg/Kg once a 
week  
18 subjects – 180mg/kg every 
three weeks 
 Adverse events – Safe and well tolerated 
Vital Signs - No Clinically significant 
changes in vital signs. 
Barros-Tizón 
201223 
 
 
Observational 
Controlled 
study 
 
 
>18 years; diagnosis of 
severe AATD (i.e. PI*ZZ 
genotypes and combinations 
of Z, rare and null alleles 
expressing AAT serum 
concentrations <11 μmol or 
50 mg/dl); recipient of 
continuous augmentation 
therapy with Trypsone or 
Prolastin ≥18 months prior 
to inclusion; available 
medical records of 18 
months before starting 
augmentation therapy. 
N=127 
Multicentre study across Spain 
Mean Age (yrs.) (SD): 
Int: 51·7(9·1) 
Sex (male) n (%): 
Int: 81(63·8) 
Mean FEV1 L (SD): 
Int: 1·25(0·5) 
 
AAT Augmentation (n=127) 
Differing treatments and dosing 
regimes 
Prolastin: 68 patients (53·5%) 
Trypsone: 59 patients (46·5%). 
Weekly Therapy: 8 patients 
(6·3%) 
Bi-Weekly Therapy: 22 patients 
(17·3%) 
Every 3 weeks: 97 patients 
(76·4%) 
The average AAT concentrate 
dose administered was 60·7 ± 
3·8 mg/kg/week  
 Exacerbation rate - Reductions in 
administration of systemic antibiotics prior to 
and following commencement of 
augmentation therapy was observed, p<0·05. 
Reductions in exacerbations per patient 
(p<0·01).  
Lung Function - Statistically significant 
decline FEV1 (L) for the total patient 
population p < 0·05 were observed however 
this is within normal decline. 
Health care cost (Hospitalisation only) – 
Saving of €416·76 per patient 
Adverse Events – Safe and well tolerated. 
Subramanian 
201224 
 
≥18 years old; FEV1/VC < 
0·7; AAT serum level < 11 
µM or < 80 mg/dL and PiZ 
N=29 
Single centre open label UK study. 3 groups; 
healthy control, non AAT related COPD, and 
AAT Augmentation (n=10) 
Prolastin: 12 Weekly 
intravenous infusions of 60 
 Change in Neutrophilic inflammation 
measured by PET scanning – No Changes 
pre and post treatment. 
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Uncontrolled 
Observational 
phenotype. AATD related COPD. Only data for AATD 
patients used. 
Of the 10 AATD patients: 
Mean Age (yrs.) (SE): 
Int: 57·2(2·9) 
Sex (male) n (%): 
Int: 9(90) 
Mean FEV1% predicted (SE): 
Int: 51·5(5·7) 
mg/kg body weight 
Campos 
201325 
 
RCT 
Double bling 
Cross-over 
Aged 18-70 years; severe 
AATD; serum AAT 
level<11 µM; diagnosis of 
COPD; FEV1 of ≥30% and 
≤80% of predicted. 
N=30 
5 centre across the USA. 
Mean Age (yrs.) (SD): 
G1: 57·4(6·34) 
G2: 59·7(6·89) 
Sex (male) n (%): 
G1: 7(46·7) 
G2: 7(46·7) 
Mean FEV1% predicted (SD): 
G1: 49(12·4) 
G2:54(14·5) 
AAT Augmentation (n=15) 
Group 1-Prolastin-C 120/60: 
Weekly intravenous infusions 
120mg/kg for 8 weeks. After a 
2 week washout period patients 
were crossed over to the 
alternate dose of 60mg/kg for a 
further 8 weeks. 
Control (n=15) 
Group 2-Prolastin-C 60/ 120 
:Weekly intravenous infusions 
60mg/kg for 8 weeks. After a 2 
week washout period patients 
were crossed over to the 
alternate dose of 120mg/kg for 
a further 8 weeks. 
Biochemical - trough serum alpha PI 
concentration higher in 120mg/Kg than 60 
mg/kg 
Adverse Events - No clinically significant 
defences between treatment groups. Drug 
well tolerated 
Sandhaus 
201426 
 
RCT 
double blind, 
partial 
crossover 
≥18 years; lung disease 
related to “at-risk” alleles 
i.e. null and deficient alleles 
associated with plasma 
levels <11 µM organ 
transplant  
N=50 
3 Sites across the USA 
Mean Age (yrs.) (SD): 
Int: 55·4(7·7) 
Cont: 55·7(9·2) 
 
Sex (male) n (%): 
Int: 17(51·5) 
Cont: 8(47·1) 
Mean FEV1% predicted (SD): 
Int: 46·05(17·17) 
Cont: 47·24(22·8) 
AAT Augmentation (n=33) 
Glassia: 12 weekly intravenous 
infusions 60mg/kg per week. 
An optional 12 week open label 
trial was an option after this 
time. 
Control (n=17) 
Prolastin: 12 weekly 
intravenous infusions 60mg/kg 
per week. An optional 12 week 
open label trial was an option 
after this time. 
Adverse Events - No clinically significant 
defences between treatment groups. 
Biochemical – No inferiority observed 
Lung Function - Mean FEV1 and % 
predicted were similar at baseline, week 12 
and 24 for both groups. 
 
 
Surgical management 
Lung Transplant 
Author year  
Study design  
Population Inclusion 
Criteria 
Participants Intervention (N) Comparator (N) Outcomes 
Breen 199227 
 
Retrospective 
registry 
review 
Recipient of Lung transplant 
in the USA between October 
1987 to December 1991 
N=8959 thoracic organ transplants. Only Lung 
transplants were considered due to data 
reporting. 
Of all 699 lung transplants: 
Sex (male) n (%): 
325(46·5%) 
Lung Transplant (n=99) 
due to AATD related 
emphysema within the USA 
within study period 
Control (n=600 of which 396 
list primary indication for 
transplant) 
Lung Transplant: for other 
cause not due to AATD related 
disease within the USA within 
study period 
Mortality - COPD/Emphysema group 
(75·4%±4·4SE) over the AATD group 
(64·4%±5·4SE). No statistical significance. 
Cassivi 
200228 
 
Retrospective 
Standard lung transplant 
recipient criteria was used. 
Disabling lung disease with a 
limited prognosis and no 
N=306  
Single centre retrospective registry review 
between 1988 and 2000 in USA. 
Mean Age (yrs.) (SD): 
Lung Transplant (n=86) 
Lung transplantation due to 
AATD. 
Follow up to 5 years 
Control (n=220) 
Lung transplantation not due to 
AATD related disease. 
Morbidity and Mortality – No superior 
survival rates. 
Lung Function - FEV1, FVC, PaCO2 No 
significant differences 
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registry 
review 
other systemic illness that 
would complicate or be 
complicated by lung 
transplantation and 
immunosuppression. 
Int: 48·9(6·3) 
Cont: 55·2(6·4) 
Sex (male) n (%): 
Int: 57(66·3) 
Cont: 86(39·1)  
Mean FEV1% predicted (SD): 
Int: 54(17) 
Cont: 51(14) 
6 Minute walk test - No significant 
differences. 
de Perrot 
200429 
 
Retrospective 
registry 
review 
All transplants at the site 
were considered for inclusion 
and recipients were selected 
according to the guidelines 
outlined by the International 
Society for Heart and Lung 
Transplantation 
and the American Thoracic 
Society. 
N=501 
Single Canadian site Lung Transplantations 
between 1983 and 2003. 
Total cohort of 501 only 151 have report of 
AATD and Non-AATD related emphysema. 
Only full cohort demographic available. 
Sex (male) n (%): 
Full cohort: 263(52·5) 
Lung Transplant (n=63) 
Patients with a diagnosis of 
AATD undergoing lung 
transplant 
Control Lung Transplant 
(n=88) 
Patients with normal AAT 
serum levels and non-AATD 
related emphysema undergoing 
lung transplant. 
Mortality – Significantly better survival for 
control group, COPD, compared to AATD 
group=0·04. 
Burton 
200530 
 
Retrospective 
registry 
review 
Selection for transplantation 
was in accordance with the 
Institute for Heart and Lung 
Transplant and the European 
Respiratory Society. 
N=362 
Single Danish site report of Lung 
Transplantation 1992 - 2003. 
349 had a reason for transplant recorded; 
analysis limited to these 
Of the 349 with diagnosis: 
Age, yrs. (range): 
Int median: 49(18-65) 
Cont mean: 39(11-71) 
Sex (male) n (%): 
Int: 16(53·5) 
Cont: 107(40·7)  
Lung Transplant (n=86) 
Patients undergoing lung 
transplantation with a primary 
diagnosis of AATD. All 
transplant types were 
considered including Single, 
Double (sequential or bloc) and 
heart lung transplant. 
Control Group (n=263) 
Patients undergoing lung 
transplantation with a primary 
diagnosis of COPD, Cystic 
Fibrosis, Pulmonary Fibrosis 
(PF), Eisenmengers or Primary 
Pulmonary Hypertension. All 
transplant types were 
considered as in AATD 
Mortality: 90day survival better than PF, 
Eisenmengers or 1e Pulmonary 
Hypertension. Improved Survival at 1 and 3 
years over PF. Comparable 5 and 10 year 
survival with other reasons for Tx 
Gunes 200631 
 
Retrospective 
registry 
review 
Standard Lung transplant 
screening was carried. 
N=173 
Single centre registry 1989–2003 in Australia. 
Mean Age (yrs.) (SD): 
Int: 47·8(6·1) 
Cont: 51·7(4·7) 
Sex (male) n (%): 
Int: 18() 
Cont: 57()  
Mean FEV1% predicted (SD): 
Int: 17(8) 
Cont: 16(8) 
Lung Transplant (n=61) 
Patients undergoing lung 
transplantation with a primary 
diagnosis of Emphysema 
related to AATD. All transplant 
types were considered 
including Single, Double and 
heart lung transplant. 
Lung Transplant (n=112) 
Patients undergoing lung 
transplantation with a primary 
diagnosis of smoking-related 
emphysema. All transplant 
types were considered as for 
AATD 
Mortality – no survival difference between 
the groups. 
Christie 
200832 
 
Retrospective 
registry 
review 
Eligible for Lung 
transplantation in accordance 
with the Institute for Heart 
and Lung Transplant 
guidelines. 
N=19792 
The Registry of the International Society for 
Heart and Lung Transplantation (ISHLT), 
USA, between 1984 and 30/06/2007. 
No subgroup demographic data available. 
Lung Transplant (n=1509) 
Patients on the ISHLT registry 
with a primary diagnosis of 
AATD. 
Lung Transplant (n=18283) 
Patients on the ISHLT registry 
with a primary diagnosis other 
than AATD 
Mortality - superior 10 year survival in 
AATD over COPD and IPF 
Tanash 
201133 
Eligible for Lung 
transplantation in accordance 
N=153 
All patients in Swedish AATD Registry 1990 – 
Lung Transplant (n=83) 
83 PiZZ patients with severe 
Control (n=70) 
After exclusions 70 matched 
Mortality - 1, 3, 5 and 10 years.  
Survival benefit in lung transplant 
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Retrospective 
case control 
Study 
with international criteria; 
PiZZ; aged >18. 
June 2010. 
Mean Age (yrs.) (Range): 
Int: 52(32-66) 
Cont: 54(35-70) 
Sex (male) n (%): 
Int: 48(58) 
Cont: 42(60)  
Mean FEV1% predicted (SD): 
Int: 22(9) 
Cont: 23(6) 
emphysema underwent Lung 
Transplant in Sweden. 
Mean follow up 7±5 years 
AATD controls who fulfilled 
the international criteria for 
Lung Transplant were included 
who were not transplanted 
during the same period. 
(p=0·006); improved estimated median 
survival in transplant of 11 years (95% [CI] 
9 to 14 years) compared to no transplant 
median survival 5 years (4 to 6). 
Banga 201434 
 
Retrospective 
Cohort 
Lung transplant recipients 
with an indication of COPD 
(AATD or AAT-replete) 
within study investigation 
period. 
N=276 
Patient undergoing LT at a single centre from 
June 1991 – Jan 2008 USA. Registry data 
Cleveland Clinic LT patients  
Mean Age (yrs.) (SD): 
Int: 49(7·5) 
Cont: 57(6·1) 
Sex (male) n (%): 
Int: 27(60) 
Cont: 114(49)  
Mean FEV1% predicted (SD): 
Int: 20(5·4) 
Cont: 20(7·1) 
Lung Transplant (n=45) 
Patients undergoing Lung 
Transplant with an indication of 
COPD related to AATD 
Controls (n=231) 
Patients undergoing Lung 
Transplant with an indication 
AAT-replete COPD  
Lung Function - No significant differences 
Mortality - No significant differences 
Post-transplant cellular rejection - No 
significant differences. 
Bredahl 
201435 
 
Retrospective 
observational 
cohort study. 
Lung Transplant recipient at 
the single site study; AAT 
levels <11 µM or 0·5g/L, 
Genotype PiZZ or PiSZ. 
N=258 
Single Danish centre recruited between Jan 
2004 and Dec 2012. Comparisons between 
COPD/Emphysema group and AATD. 
Of the 126 COPD/Emphysema and AATD 
groups: 
Mean Age (yrs.) (SD): 
Int: 53·0(7·2) 
Cont: 54·6(6·9) 
Sex (male) n (%):  
Int: 31(61) 
Cont: 27(36) 
Lung Transplant AATD (n=51) 
Patients undergoing Lung 
transplant who have confirmed 
AATD 
Lung Transplant (n=75) 
Patients undergoing Lung 
transplant who have non-
AATD related 
COPD/Emphysema. 
Post transplant Laparotomy - AATD group 
has significantly increased risk of early post-
operative laparotomy (estimated odds ratio 
5·74, 95%CI 2·15 to 15·35) 
Mortality – No differences between groups 
Inci 201436 
 
Retrospective 
registry 
review. 
Lung transplant recipient 
within study investigation 
period. 
N= 108 
Single centre review between November 1992 
and August 2013 in Switzerland. Only group 
demographics supplied as conference abstract. 
Of the completers: 
Mean Age (yrs.) (range): 
56·6 (31-68) 
Lung Transplant (n=31) 
AATD patients receiving lung 
transplantation. 
Lung Transplant (n=77) 
Non-AATD related COPD 
patients receiving lung 
transplantation. 
Mortality – 30-day, 1 and 5 year. No 
survival benefits. 
Stone 201637 
 
Retrospective 
Registry 
Cohort Study 
Patients attending the 
ADAPT Programme 
(Antitrypsin Deficiency 
Assessment and Programme 
for Treatment), between May 
1996 and 12th December 
N= 170 
AATD patients from the UK national registry. 
Transplant performed at multiple centres 
across the UK. 3 separate matching groups. 
Mean Age (yrs.) (SE): 
Int: 53·6(1·18) 
Lung Transplant (n=32 ) 
AATD patients receiving lung 
transplantation at a UK centre. 
Control (Group1 n=48 & 
Group 2 n=60, Group1 n=30) 
Matched AATD not receiving 
lung transplant. 
Group 1 – Matched at baseline 
for age, smoking, BMI, FEV1, 
Mortality – No statistically significant 
survival benefit transplant 10·1years to non-
transplant 8·4 years p=0·95 . 
Quality of Life – Improvements post 
transplant in SGRQ, p<0·01. 
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2011; PiZZ genotype, AAT 
augmentation therapy naïve. 
Cont1: 53·0(0·98) 
Cont2: 54·8(0·9) 
Cont3: 53·8(47·8-57·6) [Median (IQR)] 
Sex (male) n (%): 
Int: 23 (72) 
Cont1: 34(71) 
Cont2: 42(70) 
Cont3: 21(70) 
Mean FEV1% predicted (SE): 
Int: 32·1(1·47) 
Cont1: 26·3(1·08) 
Cont2: 25·1(1) 
Cont3: 25·3(21·3-31·4) [Median (IQR)] 
Co-morbidity. 
Group 2 – As Group 1 but 
matched at point of transplant 
with the addition of measures 
of gas transfer. 
Group 3 - As Group 2 with the 
addition of measures of SGRQ. 
 
Lung Volume Reduction 
Author year  
Study design  
Population Inclusion 
Criteria 
Participants Intervention (N) Comparator (N) Outcomes 
Cassina 
199838 
 
Prospective 
cohort 
observational 
FEV1<1·1 L and TLC 
>120% of the predicted 
value;  
MRC dyspnoea score >2 
Poor QoL (SF 36)  
Radiographic evidence of 
heterogeneous emphysema 
with target zones for LVRS; 
absence of bullae >5cm; 
matched ventilation–
perfusion scan. 
N=30 
Consecutive patients attending single centre 
for LVRS in Switzerland. 
Mean Age (yrs.) (SD): 
Int: 49(10) 
Cont: 58(11) 
Sex (male) n (%): 
Int: 7(58·3) 
Cont: 15(83·3)  
Mean FEV1% predicted (SD): 
Int: 24(7) 
Cont: 31(6) 
LVRS (n=12) 
Bilateral LVRS for AATD 
related disease: patients with a 
diagnosis of AATD undergoing 
bilateral LVRS 
 
Control LVRS (n=18) 
Bilateral LVRS for Non-AATD 
related disease: patients 
undergoing bilateral LVRS 
who do not have AATD. 
Lung Function - FEV1 superior benefits at 6, 
12 and 24 months in non-AATD related 
COPD p<0·05. 6MWT significant benefits 
control v AATD at 12 and 24 months, 
p<0·05 
MRC dyspnoea score – Non AATD COPD 
patients less breathless than AATD at 
24months 
Fujimoto 
200239 
 
Prospective 
observational. 
Marked hyperinﬂation; 
radiographic evidence of 
heterogeneous emphysema; 
FEV1<1·2 L or FEV120–
35%; TLC >120%; RV 
>250%; MRC dyspnea score 
≥2; poor QoL (SF-36); 
Abstinence from smoking; 
Acceptable nutritional status; 
and rehabilitation potential 
N=88 
Prospective enrolment from single site in 
Essen Germany of patients undergoing LVRS 
for severe Emphysema. 
Only whole group data available: 
Mean Age (yrs.) (SD): 
Int:56·1(9·1) 
Sex (male) n (%): 
Int: 62(70·5) 
Mean FEV1% predicted (SEM): 
Int: 27·5(0·8) 
LVRS (n=11) 
Bilateral LVRS for AATD 
related disease: Patients with a 
diagnosis of AATD undergoing 
bilateral LVRS 
Mean Follow up was 54·2 ±2·2 
months 
LVRS (n=77) 
Bilateral LVRS for Non-AATD 
related disease: Patients 
undergoing bilateral LVRS 
who do not have AATD. 
Lung Function – AATD only observes FEV1 
benefit for 6 months whilst control group 
maintain benefit up to 2years. 
Mortality – No survival benefit between the 
two groups. 
Tutic 200440 
 
Prospective 
cohort 
observational 
Severe A1-ATD; selected for 
LVRS according to 
previously published 
Criteria. 
N= 42 
patients recruited prospectively from a single 
centre in Switzerland. 
Of the completers: 
Mean Age (yrs.) (SE): 
Int: 56(2) 
Cont: 57(1·8) 
Sex (male) n (%): 
LVRS (n=21) 
LVRS for AATD related 
disease meeting the published 
criteria for LVRS at the single 
site 
LVRS (n=21) 
LVRS for Non-AATD related 
COPD meeting the published 
criteria for LVRS at the single 
site that have emphysema but a 
clinically normal level of 
circulating AAT. 
No significant differences between AATD 
and non AATD related lung disease. 
Lung Function – Significant improvements in 
FEV1, IVC, RV/TLC p<0·05 at 6 months. 
Physiologic measures - Significant 
improvements in 6minute walk test distance 
and MRC Dyspnoe score p<0·05 at 6 
months. 
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Int: 11(52·4) 
Cont: 12(57·1)  
Mean FEV1% predicted (SE): 
Int: 27(1·9) 
Cont: 28(1·9) 
Dauriat 
200641 
 
Observational 
cohort 
Severe airﬂow obstruction 
(FEV1<40% predicted); 
hyperinﬂation; Fletcher 
dyspnea score > 2; CT scan 
evidence of heterogeneous 
emphysema. 
N=52 
All procedures performed at a single French 
centre by the same surgeon. 
Of the completers: 
Mean Age (yrs.) (SD): 
Int: 56(9) 
Cont: 54(11) 
Mean FEV1% predicted (SD): 
Int: 22·2(5·7) 
Cont: 28(11·9) 
LVRS (n=17) 
Patients with AATD underwent 
unilateral LVRS performed in 
all cases via unilateral 
thoracotomy. The worst areas 
of emphysematous lung were 
resected by stapling guided by 
the results of CT and lung 
perfusion scan. 
LVRS (n=35) 
Patients with Non-AATD 
related emphysema treated as 
per AATD patients 
Lung Function – At 1 year FEV1 is 
statistically more improved in the non AATD 
deficient, p<0·005 
Stoller 200742 
 
Retrospective 
secondary 
analysis of 
larger RCT. 
AAT serum <80 mg/Dl; 
PiZZ, PiNull or PiZNull 
phenotypes or others 
recognised as severe 
deficient; or PiSZ and 
AAT<80mg/Dl 
N=16 
Sub-group of the National Emphysema 
Treatment Trial (n=1218) RCT in LVRS in the 
USA. 
Median Age (yrs.) (Range): 
Int: 65·8(55·4-77·0) 
Cont: 67·5(50·1-70·8) 
Sex (male) n (%): 
Int: 8(80) 
Cont: 6(100)  
Median FEV1% predicted (IQR): 
Int: 27·0(26·0-32·0) 
Cont: 25·0(21·0-33·0) 
LVRS (n=10) 
Patients data randomised to a 
larger trial was extracted and 
those receiving either unilateral 
or bilateral LVRS with a target 
goal of 20% to 30% resection 
of the most disease area.  
Follow up was a maximum of 
60 months 
 
Control (n=6) 
Medical treatment/usual care: 
Patients data randomised to a 
larger trial was extracted and 
those receiving usual care with 
no surgical intervention were 
grouped. 
Mortality - higher 2 year mortality (20% 
compared to 0%) in the surgical group. 
Quality of Life – Surgical group 
demonstrated improvements in SGRQ. 
Hillerdal 
201443 
 
Retrospective 
uncontrolled 
observational 
case series. 
Homozygotic 
AATD;<80years of age; RV 
≥140%; FEV1 15-45% 
predicted; CT confirmed 
severe heterogeneous 
emphysema; symptoms 
severely restricting QOL; 
Lack of other serious 
disease; Optimal medical 
management including 
Smoke Cessation; 
vaccination; LTOT and PR. 
N=15 
Single Swedish centre; all patients August 
2008 –January 2012. 
Of the completers: 
Mean Age (yrs.) (range): 
Int: 64(48-79) 
Sex (male) n (%): 
Int: 7(46·7) 
Mean FEV1% predicted: 
Int: 25 
Endobronchial Lung Volume 
Reduction (n=15) 
Consecutive AATD patients 
referred for and receiving 
Endobronchial Lung Volume 
Reduction (ELVR-Zephyr 
Valves-Pulmonx Inc.). 
 Lung Function change- significant benefits in 
mean FEV1 at 6 months, 1 year and 2 years 
(p=0.0022, p=0.0067 and p=0.033 
respectively). 
Safety – valves can be safely deployed in 
carefully selected patients. 
 
 
Medical managements used in usual COPD 
Author year  
Study design  
Population Inclusion 
Criteria 
Participants Intervention (N) Comparator (N) Outcomes 
Campos 
200844 
 
Verbal confirmation of 
diagnosis of AATD; 
members of AlphaNet; 
N= 939 
Participants were members of AlphaNet 
USA. 
Influenza Vaccinated (n=766) 
Participants performed monthly 
telephone interviews for data 
Not Vaccinated (n=173) 
Participants performed monthly 
telephone interviews for data 
Lung Function – No effect 
Exacerbations – no differences between 
exacerbations between years.  
Supplementary material - Edgar RG et al - International Journal of COPD March 2017 
15 
 
Observational 
study  
receiving AAT 
augmentation therapy; 
Confirmed obstructive lung 
disease.  
Sex (male) n (%): 
Int: 86 (49·7) 
Cont: 87 (50·3)  
collection including data on 
vaccination. They were 
requested to submit recent 
available lung function data.  
Between Week 40 2003 to week 
20 2004. 
collection including data on 
vaccination. They were 
requested to submit recent 
available lung function data.  
Between Week 40 2003 to week 
20 2004. 
Health Care Utilisation – Vaccinated 
participants had fewer unscheduled OPD 
Dr. visits (p=0·04  and ICU hospitalisation, 
emergency 
department visits, scheduled and 
unscheduled outpatient 
visits p=0·04, and fewer ICU admissions, 
0·01 
Campos 
200945 
 
Observational 
study 
Verbal confirmation of 
diagnosis of AATD; 
members of AlphaNet; 
receiving AAT 
augmentation therapy; 
Confirmed obstructive lung 
disease. 
N= 878 
Participants were members of AlphaNet and 
self controlled with data from previous 12 
months USA. 
Mean Age (yrs.) (SD): 
Int: 54·4 (9·6) 
Sex (male) n (%): 
Int: 465 (52·9) 
Mean FEV1% predicted (SD) n=627: 
Int: 36·8 (16·9) 
Multi-modal self management 
programme (ADMAPP)  (n=878 
) 
Combination of directed patient 
self-education, organised 
supervision, health care provider 
education and outcome 
measurements. 
Self controlled (n=878) 
Use of year 1 data prior to 
implementation of ADMAPP. 
878 patients completed 22 of 24 
monthly surveys so data is 
restricted. 
 
 
Exacerbations – Frequency, severity, 
duration, medication usage  
Health Care Utilisation – Statistically 
significant improvements in some 
medications (LABA p<0·001, Theophylline 
p=0·01, systemic steroids p=0·02) and 
supplementary oxygen p<0·01 compliance 
were observed and small reductions in 
annual exacerbations (p<0·001) and their 
duration (p=0·04) were observed. There 
were no significant changes to health status 
scores  
QoL - No significant changes. 
 
Other 
Author year  
Study design  
Population Inclusion 
Criteria 
Participants Intervention (N) Comparator (N) Outcomes 
Stolk 201246 
 
RCT 
>30 years of age; females 
non-childbearing potential; 
PiZZ, PiZNull or PiNull 
genotype; 
Never/ex-smokers ≥6 
months; clinical/radiographic 
emphysema; TLCO or KCO 
<70% ; post-bronchodilator 
FEV1≤80% ; AAT 
augmentation therapy naïve; 
no oral steroids >28 days 
prior to enrolment. 
N=262  
Subjects from 10 worldwide AAT registries. 
Mean Age (yrs.) (SD): 
Int: 54·7 (8·6) 
Cont: 53·9 (8·6) 
Sex (male) n (%): 
Int: 71 (55·0) 
Cont: 73 (54·9)  
Mean FEV1% predicted (SD): 
Int: 46·4 (16·8) 
Cont: 46·8 (16·7) 
Palovarotene (n=110) 
Two capsules per day of 
Palovarotene (RO3300074) 2·5 
mg per capsule, following the 
first meal of the day taken for 12 
months. 
Placebo (n=110) 
Two capsules per day of Placebo 
following the first meal of the 
day taken for 12 months. 
Lung Function - FEV1, SVC, TLC, FRC, 
RV, KCO, DLCO (12, 24, 36 and 52 weeks) 
Lung density - measured by CT scan 
(Baseline, 6 and 12 months). 
Exacerbations - Frequency 
Adverse Events –Safe Tolerated well  
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Supplementary table 2: Risk of bias in included studies 
RCT 
Study 
Random sequence 
generation 
Allocation 
concealment 
Blinding of 
patients 
Blinding of outcome 
assessments 
Incomplete outcome data Selective Outcome 
Reporting 
Overall 
Bias 
Treatment group Control Group 
Dirksen 19991 Unclear Unclear Unclear Low Unclear Unclear Low Unclear 
Stoller 200215 Low Unclear Unclear Unclear Low Low Low Low 
Stocks 200617 Low Low Low Low Low Low Low Low 
Dirksen 20092 Low Unclear Low Low Unclear Unclear High Unclear 
Stocks 201021 Low Low Low Unclear Low Low Low Low 
Stolk 201246 Unclear Low Unclear Unclear Low Low Low Low 
Campos 201325 Low Low Low Unclear Unclear Unclear Unclear Unclear 
Sandhaus 201426 Low Unclear Low Unclear Low Low Low Low 
Chapman 20153 Low Low Low Low Low Low Unclear Low 
Prospective Controlled Observational 
Non Randomised Studies Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Overall Bias 
Campos 200844 High Unclear Low Low Low Low 
Campos 200945 High Unclear Unclear Low Low Low 
Prospective Uncontrolled Observational and Cohort 
Non Randomised Studies Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Overall Bias 
Weber 19874 Low High Unclear Low High Low 
Cassina 199838 Low Low Low Low Low Low 
Fujimoto 200239 Low Low Unclear Low Low Low 
Tutic 200440 Low High High Low High High 
Dauriat 200641 High Low Low Low Low Low 
Campos 200918 Low Low Unclear Unclear Low Low 
Campos 200919 High Unclear Unclear Low Low Unclear 
Retrospective Controlled Observational 
Non Randomised Studies Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Overall Bias 
Wewers 19875 High Unclear High High Low High 
Seersholm 199711 High High High Low Low High 
Wencker 200114 High Low Unclear Low Unclear Unclear 
Stoller 200316 High Low Low Low Low Low 
Tonelli 200920 Low Low High Low Low Low 
Tanash 201133 Unclear Unclear Low Low Low Low 
Retrospective Uncontrolled Observational 
Non Randomised Studies Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Overall Bias 
Schmidt 19886 High High High High High High 
Breen 199227 Unclear N/A Low Low Unclear Unclear 
Barker 19947 High High High Unclear Low High 
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Miravitlles 19948 Unclear Low Low Unclear Low Low 
Barker 19979 Unclear High Unclear Low Low Unclear 
Schwaiblmair 199710 Unclear High Unclear High Unclear High 
The Alpha-1-Antitrypsin Deficiency 
Registry Study Group 199812 
High High Unclear Low High High 
Wencker 199813 Low Unclear Low Low High Low 
Cassivi 200228 Low Low Low Unclear Low Low 
de Perrot 200429 Unclear N/A Low Unclear Low Unclear 
Burton 200530 Low N/A Unclear Low Low Low 
Gunes 200631 Unclear N/A Low Low Low Low 
Stoller 200742 Low Low Low Low Low Low 
Christie 200832 Low Unclear Unclear Low Unclear Unclear 
Vidal 201022 High High High Low High High 
Barros-Tizón 201223 High High Unclear Low High High 
Subramanian 201224 Low Low Low Low Unclear Low 
Banga 201434 Low Unclear Low Low Low Low 
Bredahl 201435 High Unclear Low Unclear Low Unclear 
Hillerdal 201443 Low Unclear Low Low Low Low 
Inci 201436 Low Low Low Unclear Low Low 
Stone 201637 Low Low Low Low Low Low 
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